Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.

Abstract

Gatifloxacin is an advanced-generation fluoroquinolone with demonstrated efficacy and safety as therapy for community-acquired pneumonia (CAP). As part of a phase IV postmarketing surveillance program (TeqCES), 136 outpatients with CAP whose sputum was culture-positive for Streptococcus pneumoniae were enrolled in an open-label trial of oral gatifloxacin 400 mg daily for 7 to 14 days. An antibiogram of isolates showed 100% susceptibility to gatifloxacin (MIC(90) 0.5 micro g/mL) and respective susceptibilities of 67%, 70%, and 80% to penicillin, erythromycin, and tetracycline. Clinical cure was achieved in 95.3% of evaluable patients, including seven patients infected with penicillin-resistant S. pneumoniae (MIC > or =2 micro g/mL). The bacteriologic eradication rate for S. pneumoniae was 94.5%. Diarrhea, nausea, and dizziness, the most common adverse events in CAP patients (<3%), were generally mild to moderate; no serious adverse events were recorded. These results support recommendations to treat CAP, particularly due to S. pneumoniae including multidrug-resistant strains, with the newer 8-methoxy-fluoroquinolone, gatifloxacin.

• Authors: Ronald N Jones, David R Andes, Lionel A Mandell, Samantha Gothelf, Anton F Ehrhardt, Susan C Nicholson
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 44 Issue 1 Pg. 93-100 (Sep 2002) ISSN: 0732-8893 [Print] United States
• PMID: 12376038 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Gatifloxacin

Topics

• Administration, Oral
• Adult
• Aged
• Aged, 80 and over
• Anti-Infective Agents (administration & dosage)
• Community-Acquired Infections (diagnosis, drug therapy)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Fluoroquinolones
• Follow-Up Studies
• Gatifloxacin
• Humans
• Male
• Microbial Sensitivity Tests
• Middle Aged
• Outpatients
• Pneumonia, Pneumococcal (diagnosis, drug therapy)
• Single-Blind Method
• Streptococcus pneumoniae (drug effects, isolation & purification)
• Treatment Outcome